RxDoctor Payments Data

Craig Dawkins, MD

Urology · Gulfport, MSNPI 1124026034

Payments from drug & device makers

$1,803in general payments, 2019–2025

Across 90 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$455
  • AbbVie$314
  • Bayer$146
  • Pfizer$105
  • Boston Scientific$78
  • Sumitomo Pharma America, Inc.$63
  • plus $642 from 23 others

What the payments were for

  • Food & beverage$1,803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,803 in reported general payments places this provider in the 35th percentile of 94 urology providers in Mississippi.

See all urology providers in Mississippi

Medicare billing

Part B allowed, 2024
$103,967
Medicare patients
547
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide18$258,902
MyrbetriqMirabegron54$34,739
ElmironPentosan Polysulfate Sodium15$20,457
GemtesaVibegron23$16,510
Tolterodine Tartrate ErTolterodine Tartrate89$7,125
Testosterone32$6,507
TestimTestosterone11$5,678
Tamsulosin Hcl348$3,893
Solifenacin Succinate30$3,724
Bicalutamide97$3,478
Finasteride344$3,399
Estradiol41$2,910
Potassium Citrate ErPotassium Citrate22$2,243
NitrofurantoinNitrofurantoin Macrocrystal61$1,670
Trospium Chloride ErTrospium Chloride12$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$455$293,64172 claims
Sumitomo Pharma America, Inc.Gemtesa$63$16,51023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 94 urology providers in Mississippi.

Other urology in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →